Retour sur lavenir.net
   WERELDHAVE BELGIUM 51.800 € (0,00 %)     VASTNED 28.500 € (0,00 %)     AB INBEV 68.280 € (+1,52 %)     ELIA GROUP 128.200 € (+1,18 %)     SIPEF 103.000 € (+0,78 %)     NYXOAH 1.440 € (+1,41 %)     ARGENX SE 895.200 € (-1,34 %)     CENERGY 22.740 € (-0,09 %)     GIMV 44.450 € (+1,14 %)     BANQUP GROUP 2.150 € (+11,11 %)     ACKERMANS V.HAAREN 279.200 € (+8,22 %)     TUBIZE-FIN 186.500 € (-2,20 %)     IBA 16.840 € (+1,81 %)     ONTEX GROUP 2.785 € (-0,71 %)     KINEPOLIS GROUP 46.300 € (+1,31 %)     UCB 216.500 € (-2,43 %)     MELEXIS 66.200 € (+0,30 %)     TINC 11.240 € (+0,54 %)     LOTUS BAKERIES 12 780.000 € (-1,54 %)     ONWARD MEDICAL 2.470 € (+6,93 %)     AZELIS GROUP 12.270 € (+2,25 %)     ASCENCIO 51.700 € (0,00 %)     TITAN S.A. 53.600 € (+1,71 %)     PROXIMUS 6.350 € (+0,63 %)     KBC ANCORA 94.200 € (+0,53 %)     RECTICEL 13.720 € (+7,19 %)     D'IETEREN GROUP 176.600 € (+1,49 %)     SOFINA 248.400 € (+0,65 %)     WDP 21.340 € (+0,38 %)     MONTEA 65.500 € (-0,61 %)     SHURGARD 23.000 € (-1,08 %)     FAGRON 22.500 € (0,00 %)     TESSENDERLO 23.300 € (-2,31 %)     BREDERODE 104.000 € (+0,39 %)     VIOHALCO 16.700 € (-1,42 %)     IMMOBEL 20.300 € (-3,33 %)     CMB.TECH 15.900 € (+1,92 %)     BARCO 7.930 € (+1,54 %)     COLRUYT 38.980 € (+0,46 %)     CIE BOIS SAUVAGE 296.000 € (+0,68 %)     UMICORE 23.720 € (+1,28 %)     NEXTENSA 46.000 € (+1,08 %)     DECEUNINCK 2.415 € (-1,43 %)     SOLVAY 25.760 € (+1,42 %)     BEKAERT 38.700 € (+0,52 %)     BPOST 1.308 € (+2,19 %)     RETAIL ESTATES 65.800 € (+0,46 %)     GBL 73.850 € (+0,89 %)     ECONOCOM GROUP 1.485 € (-0,67 %)     ENERGYVISION 15.140 € (+0,13 %)     CARE PROPERTY INV. 12.160 € (0,00 %)     SYENSQO 81.350 € (+2,07 %)     JENSEN-GROUP 74.600 € (+0,81 %)     KBC 132.400 € (+0,57 %)     AEDIFICA 68.350 € (0,00 %)     AGFA-GEVAERT 0.464 € (-5,31 %)     CAMPINE 200.000 € (+2,30 %)     EVS 30.250 € (+0,50 %)     MATERIALISE 6.250 € (+1,63 %)     VAN DE VELDE 30.600 € (-0,33 %)  
   WOLTERS KLUWER 70.220 € (+0,14 %)     KENDRION 19.540 € (+1,35 %)     ATOS GROUP 29.000 € (+1,68 %)     PRECIA 25.400 € (-1,55 %)     AMG 32.340 € (+1,70 %)     RELX 31.400 € (+0,51 %)     CSG 18.660 € (-2,24 %)     FLORENTAISE 1.000 € (+11,11 %)     LVMH 458.150 € (+2,40 %)     BE SEMICONDUCTOR 197.500 € (+1,28 %)     PHILIPS KON 23.080 € (-0,60 %)     PUBLICIS GROUPE SA 101.650 € (+0,35 %)     CARVOLIX 6.400 € (-2,74 %)     ALLFUNDS GROUP 8.955 € (-0,44 %)     EURAZEO 51.500 € (+1,28 %)     SCOR SE 33.800 € (+0,54 %)     SHELL PLC 39.145 € (+0,99 %)     2CRSI 27.500 € (+2,15 %)     ASM INTERNATIONAL 825.800 € (-0,19 %)     BOIRON 25.300 € (-1,56 %)     VEOLIA ENVIRON. 32.850 € (+0,83 %)     EURONEXT 164.500 € (-0,48 %)     SANOFI 77.250 € (-0,04 %)     MAGNUM 17.384 € (+0,36 %)     VALLOUREC 17.760 € (-0,39 %)     STIF 47.500 € (-0,50 %)     OCI 4.050 € (-0,25 %)     TITAN 2.220 € (-6,72 %)     ER Capital 2.220 € (-6,72 %)     SMCP 6.650 € (+1,06 %)     LHYFE 2.100 € (-1,87 %)     THALES 244.700 € (-0,81 %)     BRUNEL INTERNAT 7.730 € (+2,38 %)     POXEL 0.201 € (-0,25 %)     EIFFAGE 109.700 € (+0,83 %)     AIRBUS 203.050 € (-0,17 %)     ENGIE 24.500 € (+1,66 %)     GL EVENTS 28.750 € (+1,77 %)     UNILEVER 55.920 € (+0,70 %)     TIKEHAU CAPITAL 16.940 € (-0,35 %)     CRCAM SUD R.A.CCI 234.500 € (0,00 %)     ABN AMRO BANK N.V. 41.680 € (+2,01 %)     PHARMING GROUP 0.994 € (-1,58 %)     EUTELSAT COMMUNIC. 1.856 € (+0,35 %)     BUREAU VERITAS 27.390 € (+0,04 %)     AMUNDI 94.950 € (+0,90 %)     TOTALENERGIES 74.670 € (+0,67 %)     HERIGE 21.300 € (+0,95 %)     CEGEDIM 10.280 € (0,00 %)     OVH 15.370 € (+0,13 %)     TME PHARMA 0.146 € (+2,96 %)     MEDINCELL 24.040 € (-2,51 %)     SOCIETE GENERALE 72.350 € (+1,86 %)     MERCIALYS 11.140 € (+0,36 %)     ASML HOLDING 1 494.400 € (+0,54 %)     ESSILORLUXOTTICA 161.350 € (+2,44 %)     AIR LIQUIDE 169.800 € (+1,81 %)     DANONE 64.400 € (-0,46 %)     CARREFOUR 15.630 € (+0,22 %)     ELIS 24.060 € (+0,67 %)  
News Réglementées
23/06/2026 06:30

Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations

Lonza Group AG / Key word(s): Miscellaneous
Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations

23-Jun-2026 / 06:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Ad hoc announcement pursuant to Art. 53 LR

  • Lonza reports restated Half-Year 2025 financials, reflecting Capsules & Health Ingredients (CHI) as discontinued operations, aligned with Full-Year 2025 reporting
  • Restatement includes updated consolidated income statement and selected key performance measures

Basel, Switzerland, 23 June 2026 – Prior to the release of its Half-Year 2026 results on 22 July, Lonza has published restated Half-Year 2025 financial information reflecting the classification of its CHI business as discontinued operations, in line with its Full-Year 2025 reporting. 

In December 2024, Lonza announced its intention to divest the CHI business. As a result, the CHI results were reported as discontinued operations for the Full-Year 2025. On 6 March 2026, Lonza entered into a definitive agreement to divest the CHI business to Lone Star Funds, with closing expected in Q3 2026.

The restatement includes the consolidated income statement and selected key performance measures. The restatement has no impact on Lonza’s previously reported Full-Year 2025 results. 

The restated Half-Year 2025 financial information is available at the following link.

About Lonza

Lonza is the world’s leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across five continents, Lonza’s global team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.

Our company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. Find out more at www.lonza.com

Lonza Contact Details

Daniel Buchta
Head of Investor Relations
Lonza Group Ltd
Tel +41 61 316 2985
daniel.buchta@lonza.com

Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
victoria.morgan@lonza.com


End of Inside Information
Language:English
Company:Lonza Group AG
Münchensteinerstrasse 38
4052 Basel
Switzerland
Phone:+4161 316 81 11
Internet:www.lonza.com
ISIN:CH0013841017
Valor:1384101
Listed:SIX Swiss Exchange
EQS News ID:2351296

 
End of AnnouncementEQS News Service

2351296  23-Jun-2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière